Biofrontera AG

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, VRTX has a market cap of 112.83B. Regarding current trading prices, BFRA is priced at $2.67, while VRTX trades at $439.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas VRTX's P/E ratio is -114.72. In terms of profitability, BFRA's ROE is -1.50%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, BFRA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, REGN has a market cap of 61.10B. Regarding current trading prices, BFRA is priced at $2.67, while REGN trades at $575.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas REGN's P/E ratio is 14.64. In terms of profitability, BFRA's ROE is -1.50%, compared to REGN's ROE of +0.15%. Regarding short-term risk, BFRA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, SGEN has a market cap of 43.15B. Regarding current trading prices, BFRA is priced at $2.67, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BFRA's ROE is -1.50%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, BFRA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ALNY has a market cap of 35.23B. Regarding current trading prices, BFRA is priced at $2.67, while ALNY trades at $270.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ALNY's P/E ratio is -128.66. In terms of profitability, BFRA's ROE is -1.50%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, BFRA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ARGX has a market cap of 34.25B. Regarding current trading prices, BFRA is priced at $2.67, while ARGX trades at $560.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ARGX's P/E ratio is 43.92. In terms of profitability, BFRA's ROE is -1.50%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, BFRA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, BNTX has a market cap of 23.38B. Regarding current trading prices, BFRA is priced at $2.67, while BNTX trades at $97.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BNTX's P/E ratio is -26.94. In terms of profitability, BFRA's ROE is -1.50%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, BFRA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, BGNE has a market cap of 20.21B. Regarding current trading prices, BFRA is priced at $2.67, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BFRA's ROE is -1.50%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, BFRA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, DNA-WT has a market cap of 18.73B. Regarding current trading prices, BFRA is priced at $2.67, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BFRA's ROE is -1.50%, compared to DNA-WT's ROE of -0.66%. Regarding short-term risk, BFRA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, SMMT has a market cap of 18.63B. Regarding current trading prices, BFRA is priced at $2.67, while SMMT trades at $25.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SMMT's P/E ratio is -74.29. In terms of profitability, BFRA's ROE is -1.50%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, BFRA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, RPRX has a market cap of 14.46B. Regarding current trading prices, BFRA is priced at $2.67, while RPRX trades at $33.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RPRX's P/E ratio is 17.46. In terms of profitability, BFRA's ROE is -1.50%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, BFRA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, UTHR has a market cap of 14.02B. Regarding current trading prices, BFRA is priced at $2.67, while UTHR trades at $310.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas UTHR's P/E ratio is 12.38. In terms of profitability, BFRA's ROE is -1.50%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BFRA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, KRTX has a market cap of 12.60B. Regarding current trading prices, BFRA is priced at $2.67, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BFRA's ROE is -1.50%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, BFRA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, GMAB has a market cap of 12.48B. Regarding current trading prices, BFRA is priced at $2.67, while GMAB trades at $19.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas GMAB's P/E ratio is 10.83. In terms of profitability, BFRA's ROE is -1.50%, compared to GMAB's ROE of +0.24%. Regarding short-term risk, BFRA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, INCY has a market cap of 11.78B. Regarding current trading prices, BFRA is priced at $2.67, while INCY trades at $60.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas INCY's P/E ratio is 304.25. In terms of profitability, BFRA's ROE is -1.50%, compared to INCY's ROE of +0.01%. Regarding short-term risk, BFRA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, BMRN has a market cap of 11.77B. Regarding current trading prices, BFRA is priced at $2.67, while BMRN trades at $61.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BMRN's P/E ratio is 22.73. In terms of profitability, BFRA's ROE is -1.50%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, BFRA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, EXEL has a market cap of 10.19B. Regarding current trading prices, BFRA is priced at $2.67, while EXEL trades at $36.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas EXEL's P/E ratio is 21.01. In terms of profitability, BFRA's ROE is -1.50%, compared to EXEL's ROE of +0.24%. Regarding short-term risk, BFRA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, MRNA has a market cap of 9.94B. Regarding current trading prices, BFRA is priced at $2.67, while MRNA trades at $25.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MRNA's P/E ratio is -2.94. In terms of profitability, BFRA's ROE is -1.50%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, BFRA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, RXDX has a market cap of 9.56B. Regarding current trading prices, BFRA is priced at $2.67, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BFRA's ROE is -1.50%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BFRA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ASND has a market cap of 9.32B. Regarding current trading prices, BFRA is priced at $2.67, while ASND trades at $154.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ASND's P/E ratio is -23.51. In terms of profitability, BFRA's ROE is -1.50%, compared to ASND's ROE of +1.91%. Regarding short-term risk, BFRA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, IMGN has a market cap of 8.73B. Regarding current trading prices, BFRA is priced at $2.67, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BFRA's ROE is -1.50%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, BFRA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, TECH has a market cap of 8.45B. Regarding current trading prices, BFRA is priced at $2.67, while TECH trades at $53.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas TECH's P/E ratio is 64.94. In terms of profitability, BFRA's ROE is -1.50%, compared to TECH's ROE of +0.08%. Regarding short-term risk, BFRA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, HALO has a market cap of 8.20B. Regarding current trading prices, BFRA is priced at $2.67, while HALO trades at $66.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas HALO's P/E ratio is 17.71. In terms of profitability, BFRA's ROE is -1.50%, compared to HALO's ROE of +1.38%. Regarding short-term risk, BFRA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, CERE has a market cap of 8.19B. Regarding current trading prices, BFRA is priced at $2.67, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CERE's P/E ratio is -16.47. In terms of profitability, BFRA's ROE is -1.50%, compared to CERE's ROE of -0.99%. Regarding short-term risk, BFRA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ROIV has a market cap of 7.84B. Regarding current trading prices, BFRA is priced at $2.67, while ROIV trades at $10.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ROIV's P/E ratio is -10.99. In terms of profitability, BFRA's ROE is -1.50%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, BFRA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ROIVW has a market cap of 7.83B. Regarding current trading prices, BFRA is priced at $2.67, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, BFRA's ROE is -1.50%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, BFRA is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, RVMD has a market cap of 7.80B. Regarding current trading prices, BFRA is priced at $2.67, while RVMD trades at $41.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RVMD's P/E ratio is -11.70. In terms of profitability, BFRA's ROE is -1.50%, compared to RVMD's ROE of -0.33%. Regarding short-term risk, BFRA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, CORT has a market cap of 7.65B. Regarding current trading prices, BFRA is priced at $2.67, while CORT trades at $72.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CORT's P/E ratio is 62.72. In terms of profitability, BFRA's ROE is -1.50%, compared to CORT's ROE of +0.20%. Regarding short-term risk, BFRA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, BBIO has a market cap of 6.77B. Regarding current trading prices, BFRA is priced at $2.67, while BBIO trades at $35.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BBIO's P/E ratio is -10.02. In terms of profitability, BFRA's ROE is -1.50%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, BFRA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, MDGL has a market cap of 6.68B. Regarding current trading prices, BFRA is priced at $2.67, while MDGL trades at $300.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MDGL's P/E ratio is -16.86. In terms of profitability, BFRA's ROE is -1.50%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, BFRA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, RETA has a market cap of 6.57B. Regarding current trading prices, BFRA is priced at $2.67, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RETA's P/E ratio is -66.29. In terms of profitability, BFRA's ROE is -1.50%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BFRA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, BPMC has a market cap of 6.48B. Regarding current trading prices, BFRA is priced at $2.67, while BPMC trades at $100.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BPMC's P/E ratio is -39.96. In terms of profitability, BFRA's ROE is -1.50%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, BFRA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, JAZZ has a market cap of 6.38B. Regarding current trading prices, BFRA is priced at $2.67, while JAZZ trades at $103.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas JAZZ's P/E ratio is 14.07. In terms of profitability, BFRA's ROE is -1.50%, compared to JAZZ's ROE of +0.14%. Regarding short-term risk, BFRA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, VRNA has a market cap of 5.75B. Regarding current trading prices, BFRA is priced at $2.67, while VRNA trades at $67.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas VRNA's P/E ratio is -33.76. In terms of profitability, BFRA's ROE is -1.50%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, BFRA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, TGTX has a market cap of 5.56B. Regarding current trading prices, BFRA is priced at $2.67, while TGTX trades at $34.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas TGTX's P/E ratio is 139.96. In terms of profitability, BFRA's ROE is -1.50%, compared to TGTX's ROE of +0.12%. Regarding short-term risk, BFRA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ABCM has a market cap of 5.52B. Regarding current trading prices, BFRA is priced at $2.67, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BFRA's ROE is -1.50%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BFRA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ISEE has a market cap of 5.51B. Regarding current trading prices, BFRA is priced at $2.67, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BFRA's ROE is -1.50%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BFRA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, AXSM has a market cap of 5.42B. Regarding current trading prices, BFRA is priced at $2.67, while AXSM trades at $110.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas AXSM's P/E ratio is -19.12. In terms of profitability, BFRA's ROE is -1.50%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, BFRA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, TLX has a market cap of 5.40B. Regarding current trading prices, BFRA is priced at $2.67, while TLX trades at $16.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas TLX's P/E ratio is 179.33. In terms of profitability, BFRA's ROE is -1.50%, compared to TLX's ROE of +0.14%. Regarding short-term risk, BFRA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, IONS has a market cap of 5.34B. Regarding current trading prices, BFRA is priced at $2.67, while IONS trades at $33.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas IONS's P/E ratio is -11.21. In terms of profitability, BFRA's ROE is -1.50%, compared to IONS's ROE of -0.00%. Regarding short-term risk, BFRA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, NUVL has a market cap of 5.29B. Regarding current trading prices, BFRA is priced at $2.67, while NUVL trades at $73.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas NUVL's P/E ratio is -18.74. In terms of profitability, BFRA's ROE is -1.50%, compared to NUVL's ROE of -0.30%. Regarding short-term risk, BFRA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ALKS has a market cap of 5.16B. Regarding current trading prices, BFRA is priced at $2.67, while ALKS trades at $31.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ALKS's P/E ratio is 14.89. In terms of profitability, BFRA's ROE is -1.50%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, BFRA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ADMA has a market cap of 4.88B. Regarding current trading prices, BFRA is priced at $2.67, while ADMA trades at $20.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ADMA's P/E ratio is 25.25. In terms of profitability, BFRA's ROE is -1.50%, compared to ADMA's ROE of +0.86%. Regarding short-term risk, BFRA is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ALPN has a market cap of 4.46B. Regarding current trading prices, BFRA is priced at $2.67, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BFRA's ROE is -1.50%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, BFRA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, OPT has a market cap of 4.20B. Regarding current trading prices, BFRA is priced at $2.67, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas OPT's P/E ratio is -1.52. In terms of profitability, BFRA's ROE is -1.50%, compared to OPT's ROE of +2.60%. Regarding short-term risk, BFRA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, MRTX has a market cap of 4.12B. Regarding current trading prices, BFRA is priced at $2.67, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BFRA's ROE is -1.50%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, BFRA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, PCVX has a market cap of 4.08B. Regarding current trading prices, BFRA is priced at $2.67, while PCVX trades at $31.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas PCVX's P/E ratio is -8.31. In terms of profitability, BFRA's ROE is -1.50%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, BFRA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, KRYS has a market cap of 4.03B. Regarding current trading prices, BFRA is priced at $2.67, while KRYS trades at $139.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas KRYS's P/E ratio is 33.44. In terms of profitability, BFRA's ROE is -1.50%, compared to KRYS's ROE of +0.10%. Regarding short-term risk, BFRA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, CYTK has a market cap of 3.84B. Regarding current trading prices, BFRA is priced at $2.67, while CYTK trades at $32.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CYTK's P/E ratio is -6.07. In terms of profitability, BFRA's ROE is -1.50%, compared to CYTK's ROE of +5.40%. Regarding short-term risk, BFRA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, RYTM has a market cap of 3.75B. Regarding current trading prices, BFRA is priced at $2.67, while RYTM trades at $58.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RYTM's P/E ratio is -13.59. In terms of profitability, BFRA's ROE is -1.50%, compared to RYTM's ROE of -3.79%. Regarding short-term risk, BFRA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, RYZB has a market cap of 3.75B. Regarding current trading prices, BFRA is priced at $2.67, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BFRA's ROE is -1.50%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BFRA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, CBAY has a market cap of 3.73B. Regarding current trading prices, BFRA is priced at $2.67, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BFRA's ROE is -1.50%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, BFRA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, PTCT has a market cap of 3.65B. Regarding current trading prices, BFRA is priced at $2.67, while PTCT trades at $46.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas PTCT's P/E ratio is 7.07. In terms of profitability, BFRA's ROE is -1.50%, compared to PTCT's ROE of +0.36%. Regarding short-term risk, BFRA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, SRPT has a market cap of 3.57B. Regarding current trading prices, BFRA is priced at $2.67, while SRPT trades at $36.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SRPT's P/E ratio is -13.78. In terms of profitability, BFRA's ROE is -1.50%, compared to SRPT's ROE of +0.20%. Regarding short-term risk, BFRA is more volatile compared to SRPT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, RNA has a market cap of 3.54B. Regarding current trading prices, BFRA is priced at $2.67, while RNA trades at $29.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RNA's P/E ratio is -10.15. In terms of profitability, BFRA's ROE is -1.50%, compared to RNA's ROE of -0.26%. Regarding short-term risk, BFRA is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, SWTX has a market cap of 3.46B. Regarding current trading prices, BFRA is priced at $2.67, while SWTX trades at $46.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SWTX's P/E ratio is -13.25. In terms of profitability, BFRA's ROE is -1.50%, compared to SWTX's ROE of -0.48%. Regarding short-term risk, BFRA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, RARE has a market cap of 3.41B. Regarding current trading prices, BFRA is priced at $2.67, while RARE trades at $36.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RARE's P/E ratio is -5.74. In terms of profitability, BFRA's ROE is -1.50%, compared to RARE's ROE of -1.94%. Regarding short-term risk, BFRA is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, AKRO has a market cap of 3.31B. Regarding current trading prices, BFRA is priced at $2.67, while AKRO trades at $41.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas AKRO's P/E ratio is -11.07. In terms of profitability, BFRA's ROE is -1.50%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, BFRA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ACLX has a market cap of 3.28B. Regarding current trading prices, BFRA is priced at $2.67, while ACLX trades at $59.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ACLX's P/E ratio is -29.75. In terms of profitability, BFRA's ROE is -1.50%, compared to ACLX's ROE of -0.22%. Regarding short-term risk, BFRA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, CRSP has a market cap of 3.25B. Regarding current trading prices, BFRA is priced at $2.67, while CRSP trades at $37.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CRSP's P/E ratio is -8.66. In terms of profitability, BFRA's ROE is -1.50%, compared to CRSP's ROE of -0.18%. Regarding short-term risk, BFRA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, SLNO has a market cap of 3.21B. Regarding current trading prices, BFRA is priced at $2.67, while SLNO trades at $69.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SLNO's P/E ratio is -15.97. In terms of profitability, BFRA's ROE is -1.50%, compared to SLNO's ROE of -0.75%. Regarding short-term risk, BFRA is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, VKTX has a market cap of 3.18B. Regarding current trading prices, BFRA is priced at $2.67, while VKTX trades at $28.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas VKTX's P/E ratio is -24.40. In terms of profitability, BFRA's ROE is -1.50%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, BFRA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, CRNX has a market cap of 3.12B. Regarding current trading prices, BFRA is priced at $2.67, while CRNX trades at $33.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CRNX's P/E ratio is -9.03. In terms of profitability, BFRA's ROE is -1.50%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, BFRA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, SRRK has a market cap of 3.08B. Regarding current trading prices, BFRA is priced at $2.67, while SRRK trades at $32.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SRRK's P/E ratio is -13.14. In terms of profitability, BFRA's ROE is -1.50%, compared to SRRK's ROE of -1.29%. Regarding short-term risk, BFRA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, LEGN has a market cap of 2.97B. Regarding current trading prices, BFRA is priced at $2.67, while LEGN trades at $32.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas LEGN's P/E ratio is -33.73. In terms of profitability, BFRA's ROE is -1.50%, compared to LEGN's ROE of -0.16%. Regarding short-term risk, BFRA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, MRUS has a market cap of 2.94B. Regarding current trading prices, BFRA is priced at $2.67, while MRUS trades at $42.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MRUS's P/E ratio is -12.66. In terms of profitability, BFRA's ROE is -1.50%, compared to MRUS's ROE of -0.35%. Regarding short-term risk, BFRA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ACAD has a market cap of 2.93B. Regarding current trading prices, BFRA is priced at $2.67, while ACAD trades at $17.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ACAD's P/E ratio is 12.89. In terms of profitability, BFRA's ROE is -1.50%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, BFRA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, CPRX has a market cap of 2.91B. Regarding current trading prices, BFRA is priced at $2.67, while CPRX trades at $23.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CPRX's P/E ratio is 18.19. In terms of profitability, BFRA's ROE is -1.50%, compared to CPRX's ROE of +0.26%. Regarding short-term risk, BFRA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, MORF has a market cap of 2.86B. Regarding current trading prices, BFRA is priced at $2.67, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MORF's P/E ratio is -14.88. In terms of profitability, BFRA's ROE is -1.50%, compared to MORF's ROE of -0.27%. Regarding short-term risk, BFRA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, MOR has a market cap of 2.86B. Regarding current trading prices, BFRA is priced at $2.67, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MOR's P/E ratio is -12.64. In terms of profitability, BFRA's ROE is -1.50%, compared to MOR's ROE of +7.43%. Regarding short-term risk, BFRA is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, PTGX has a market cap of 2.81B. Regarding current trading prices, BFRA is priced at $2.67, while PTGX trades at $45.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas PTGX's P/E ratio is 58.04. In terms of profitability, BFRA's ROE is -1.50%, compared to PTGX's ROE of +0.48%. Regarding short-term risk, BFRA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, MTSR has a market cap of 2.77B. Regarding current trading prices, BFRA is priced at $2.67, while MTSR trades at $26.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MTSR's P/E ratio is -13.00. In terms of profitability, BFRA's ROE is -1.50%, compared to MTSR's ROE of -0.31%. Regarding short-term risk, BFRA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, XENE has a market cap of 2.75B. Regarding current trading prices, BFRA is priced at $2.67, while XENE trades at $35.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas XENE's P/E ratio is -11.91. In terms of profitability, BFRA's ROE is -1.50%, compared to XENE's ROE of -0.29%. Regarding short-term risk, BFRA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, KDNY has a market cap of 2.71B. Regarding current trading prices, BFRA is priced at $2.67, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas KDNY's P/E ratio is -12.47. In terms of profitability, BFRA's ROE is -1.50%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, BFRA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, MYOV has a market cap of 2.62B. Regarding current trading prices, BFRA is priced at $2.67, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MYOV's P/E ratio is -14.05. In terms of profitability, BFRA's ROE is -1.50%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, BFRA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, MLTX has a market cap of 2.57B. Regarding current trading prices, BFRA is priced at $2.67, while MLTX trades at $40.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MLTX's P/E ratio is -21.46. In terms of profitability, BFRA's ROE is -1.50%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, BFRA is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, IMVT has a market cap of 2.47B. Regarding current trading prices, BFRA is priced at $2.67, while IMVT trades at $14.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas IMVT's P/E ratio is -5.55. In terms of profitability, BFRA's ROE is -1.50%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, BFRA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, VCYT has a market cap of 2.41B. Regarding current trading prices, BFRA is priced at $2.67, while VCYT trades at $30.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas VCYT's P/E ratio is 99.23. In terms of profitability, BFRA's ROE is -1.50%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, BFRA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, PRVB has a market cap of 2.38B. Regarding current trading prices, BFRA is priced at $2.67, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas PRVB's P/E ratio is -16.43. In terms of profitability, BFRA's ROE is -1.50%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, BFRA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, LBPH has a market cap of 2.34B. Regarding current trading prices, BFRA is priced at $2.67, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas LBPH's P/E ratio is -26.66. In terms of profitability, BFRA's ROE is -1.50%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, BFRA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, APGE has a market cap of 2.31B. Regarding current trading prices, BFRA is priced at $2.67, while APGE trades at $39.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas APGE's P/E ratio is -11.99. In terms of profitability, BFRA's ROE is -1.50%, compared to APGE's ROE of -0.22%. Regarding short-term risk, BFRA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, DICE has a market cap of 2.27B. Regarding current trading prices, BFRA is priced at $2.67, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas DICE's P/E ratio is -21.91. In terms of profitability, BFRA's ROE is -1.50%, compared to DICE's ROE of +0.56%. Regarding short-term risk, BFRA is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, MIRM has a market cap of 2.26B. Regarding current trading prices, BFRA is priced at $2.67, while MIRM trades at $45.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MIRM's P/E ratio is -24.63. In terms of profitability, BFRA's ROE is -1.50%, compared to MIRM's ROE of -0.38%. Regarding short-term risk, BFRA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, APLS has a market cap of 2.20B. Regarding current trading prices, BFRA is priced at $2.67, while APLS trades at $17.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas APLS's P/E ratio is -10.95. In terms of profitability, BFRA's ROE is -1.50%, compared to APLS's ROE of -0.79%. Regarding short-term risk, BFRA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, NAMSW has a market cap of 2.17B. Regarding current trading prices, BFRA is priced at $2.67, while NAMSW trades at $8.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas NAMSW's P/E ratio is N/A. In terms of profitability, BFRA's ROE is -1.50%, compared to NAMSW's ROE of -0.50%. Regarding short-term risk, BFRA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, BCRX has a market cap of 2.16B. Regarding current trading prices, BFRA is priced at $2.67, while BCRX trades at $10.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BCRX's P/E ratio is -39.77. In terms of profitability, BFRA's ROE is -1.50%, compared to BCRX's ROE of +0.15%. Regarding short-term risk, BFRA is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, NAMS has a market cap of 2.16B. Regarding current trading prices, BFRA is priced at $2.67, while NAMS trades at $19.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas NAMS's P/E ratio is -7.51. In terms of profitability, BFRA's ROE is -1.50%, compared to NAMS's ROE of -0.50%. Regarding short-term risk, BFRA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, DNLI has a market cap of 2.15B. Regarding current trading prices, BFRA is priced at $2.67, while DNLI trades at $14.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas DNLI's P/E ratio is -5.55. In terms of profitability, BFRA's ROE is -1.50%, compared to DNLI's ROE of -0.31%. Regarding short-term risk, BFRA is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, CALT has a market cap of 2.15B. Regarding current trading prices, BFRA is priced at $2.67, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CALT's P/E ratio is -22.73. In terms of profitability, BFRA's ROE is -1.50%, compared to CALT's ROE of -2.10%. Regarding short-term risk, BFRA is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, VCEL has a market cap of 2.15B. Regarding current trading prices, BFRA is priced at $2.67, while VCEL trades at $42.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas VCEL's P/E ratio is 213.25. In terms of profitability, BFRA's ROE is -1.50%, compared to VCEL's ROE of +0.04%. Regarding short-term risk, BFRA is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, AAPG has a market cap of 2.10B. Regarding current trading prices, BFRA is priced at $2.67, while AAPG trades at $24.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas AAPG's P/E ratio is -32.70. In terms of profitability, BFRA's ROE is -1.50%, compared to AAPG's ROE of N/A. Regarding short-term risk, BFRA is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, BHVN has a market cap of 2.09B. Regarding current trading prices, BFRA is priced at $2.67, while BHVN trades at $20.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BHVN's P/E ratio is -2.21. In terms of profitability, BFRA's ROE is -1.50%, compared to BHVN's ROE of -2.38%. Regarding short-term risk, BFRA is more volatile compared to BHVN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, KYMR has a market cap of 2.09B. Regarding current trading prices, BFRA is priced at $2.67, while KYMR trades at $32.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas KYMR's P/E ratio is -10.80. In terms of profitability, BFRA's ROE is -1.50%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, BFRA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, IBRX has a market cap of 2.08B. Regarding current trading prices, BFRA is priced at $2.67, while IBRX trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas IBRX's P/E ratio is -3.81. In terms of profitability, BFRA's ROE is -1.50%, compared to IBRX's ROE of +0.63%. Regarding short-term risk, BFRA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, LGND has a market cap of 2.05B. Regarding current trading prices, BFRA is priced at $2.67, while LGND trades at $106.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas LGND's P/E ratio is -483.55. In terms of profitability, BFRA's ROE is -1.50%, compared to LGND's ROE of -0.00%. Regarding short-term risk, BFRA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, HRMY has a market cap of 2.05B. Regarding current trading prices, BFRA is priced at $2.67, while HRMY trades at $35.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas HRMY's P/E ratio is 13.61. In terms of profitability, BFRA's ROE is -1.50%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, BFRA is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, BLTE has a market cap of 1.97B. Regarding current trading prices, BFRA is priced at $2.67, while BLTE trades at $61.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BLTE's P/E ratio is -52.53. In terms of profitability, BFRA's ROE is -1.50%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, BFRA is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, KNSA has a market cap of 1.96B. Regarding current trading prices, BFRA is priced at $2.67, while KNSA trades at $26.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas KNSA's P/E ratio is -111.83. In terms of profitability, BFRA's ROE is -1.50%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, BFRA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, CGON has a market cap of 1.92B. Regarding current trading prices, BFRA is priced at $2.67, while CGON trades at $25.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CGON's P/E ratio is -17.87. In terms of profitability, BFRA's ROE is -1.50%, compared to CGON's ROE of -0.15%. Regarding short-term risk, BFRA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at N/A. In comparison, ARWR has a market cap of 1.92B. Regarding current trading prices, BFRA is priced at $2.67, while ARWR trades at $13.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ARWR's P/E ratio is -2.71. In terms of profitability, BFRA's ROE is -1.50%, compared to ARWR's ROE of -2.43%. Regarding short-term risk, BFRA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.